Reassessing Twenty Years of Vaccine Development Against Tuberculosis
Title | Reassessing Twenty Years of Vaccine Development Against Tuberculosis PDF eBook |
Author | Ulrich E. Schaible |
Publisher | Frontiers Media SA |
Total Pages | 110 |
Release | 2018-03-23 |
Genre | |
ISBN | 2889454460 |
Tuberculosis (TB) remains the prime bacterial infection worldwide with 10.4 million infections and a death toll of 1.7 million people in 2016 according to WHO statistics. Tuberculosis is caused by members of the Mycobacterium tuberculosis complex, facultative intracellular bacteria able to thrive within otherwise potent innate defense cells, the macrophages. In a world of increasing numbers of infections with drug resistant M. tuberculosis strains, the daunting race between developing new therapeutics and emerging resistant strains will hardly produce a winner. This cycle can only be broken by enhancing population wide immune control through a better vaccine as the only one currently in use, M. bovis Bacillus Calmette Guerin (BCG). The protective efficacy of BCG against pulmonary tuberculosis in all age groups is dissatisfying and geographically highly diverse with the tropical areas showing the lowest efficacy rates. Despite worldwide vaccination coverage, the impact of BCG on the steep decrease of tuberculosis incidence rates in the developed world seems therefore questionable and can rather be attributed to improved social, housing and nutritional conditions, better health care, surveillance and treatment systems. The last 15 years saw tremendous efforts to improve vaccination strategies against tuberculosis. Different paths of vaccine approaches were followed including genetically improved BCG strains, attenuated M. tuberculosis variants, recombinant viral vectors and subunit vaccine candidates combined with novel more potent adjuvants. With the first novel vaccine candidates being evaluated in clinical phases II and III and initial results chastening the expectations, a critical reassessment of all candidates is inevitable. Here, we assembled experts to review and assess the current status of novel anti-tuberculosis vaccine candidates, their efficacy and prospects for implementation as well as the pitfalls and possible measures for improvement.
Reassessing Twenty Years of Vaccine Development Against Tuberculosis
Title | Reassessing Twenty Years of Vaccine Development Against Tuberculosis PDF eBook |
Author | |
Publisher | |
Total Pages | 0 |
Release | 2018 |
Genre | |
ISBN |
Tuberculosis (TB) remains the prime bacterial infection worldwide with 10.4 million infections and a death toll of 1.7 million people in 2016 according to WHO statistics. Tuberculosis is caused by members of the Mycobacterium tuberculosis complex, facultative intracellular bacteria able to thrive within otherwise potent innate defense cells, the macrophages. In a world of increasing numbers of infections with drug resistant M. tuberculosis strains, the daunting race between developing new therapeutics and emerging resistant strains will hardly produce a winner. This cycle can only be broken by enhancing population wide immune control through a better vaccine as the only one currently in use, M. bovis Bacillus Calmette Guerin (BCG). The protective efficacy of BCG against pulmonary tuberculosis in all age groups is dissatisfying and geographically highly diverse with the tropical areas showing the lowest efficacy rates. Despite worldwide vaccination coverage, the impact of BCG on the steep decrease of tuberculosis incidence rates in the developed world seems therefore questionable and can rather be attributed to improved social, housing and nutritional conditions, better health care, surveillance and treatment systems. The last 15 years saw tremendous efforts to improve vaccination strategies against tuberculosis. Different paths of vaccine approaches were followed including genetically improved BCG strains, attenuated M. tuberculosis variants, recombinant viral vectors and subunit vaccine candidates combined with novel more potent adjuvants. With the first novel vaccine candidates being evaluated in clinical phases II and III and initial results chastening the expectations, a critical reassessment of all candidates is inevitable. Here, we assembled experts to review and assess the current status of novel anti-tuberculosis vaccine candidates, their efficacy and prospects for implementation as well as the pitfalls and possible measures for improvement.
Immunization Safety Review
Title | Immunization Safety Review PDF eBook |
Author | Institute of Medicine |
Publisher | National Academies Press |
Total Pages | 304 |
Release | 2002-07-02 |
Genre | Medical |
ISBN | 0309169887 |
By two years of age, healthy infants in the United States can receive up to 20 vaccinations to protect against 11 diseases. Although most people know that vaccines effectively protect against serious infectious diseases, approximately one-quarter of parents in a recent survey believe that infants get more vaccines than are good for them, and that too many immunizations could overwhelm an infant's immune system. The Immunization Safety Review Committee reviewed the evidence regarding the hypothesis that multiple immunizations increase the risk for immune dysfunction. Specifically, the committee looked at evidence of potential biological mechanisms and at epidemiological evidence for or against causality related to risk for infections, the autoimmune disease type 1 diabetes, and allergic disorders.
Priorities for the National Vaccine Plan
Title | Priorities for the National Vaccine Plan PDF eBook |
Author | Institute of Medicine |
Publisher | National Academies Press |
Total Pages | 368 |
Release | 2010-05-17 |
Genre | Medical |
ISBN | 0309156203 |
Vaccination is a fundamental component of preventive medicine and public health. The use of vaccines to prevent infectious diseases has resulted in dramatic decreases in disease, disability, and death in the United States and around the world. The current political, economic, and social environment presents both opportunities for and challenges to strengthening the U.S. system for developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. Priorities for the National Vaccine Plan examines the extraordinarily complex vaccine enterprise, from research and development of new vaccines to financing and reimbursement of immunization services. Priorities for the National Vaccine Plan examines the extraordinarily complex vaccine enterprise, from research and development of new vaccines to financing and reimbursement of immunization services. The book makes recommendations about priority actions in the update to the National Vaccine Plan that are intended to achieve the objectives of disease prevention and enhancement of vaccine safety. It is centered on the plan's five goals in the areas of vaccine development, safety, communication, supply and use, and global health.
Pocket Book of Hospital Care for Children
Title | Pocket Book of Hospital Care for Children PDF eBook |
Author | World Health Organization |
Publisher | World Health Organization |
Total Pages | 442 |
Release | 2013 |
Genre | Business & Economics |
ISBN | 9241548371 |
The Pocket Book is for use by doctors nurses and other health workers who are responsible for the care of young children at the first level referral hospitals. This second edition is based on evidence from several WHO updated and published clinical guidelines. It is for use in both inpatient and outpatient care in small hospitals with basic laboratory facilities and essential medicines. In some settings these guidelines can be used in any facilities where sick children are admitted for inpatient care. The Pocket Book is one of a series of documents and tools that support the Integrated Managem.
Ending Neglect
Title | Ending Neglect PDF eBook |
Author | Institute of Medicine |
Publisher | National Academies Press |
Total Pages | 288 |
Release | 2000-08-31 |
Genre | Medical |
ISBN | 0309171946 |
Tuberculosis emerged as an epidemic in the 1600s, began to decline as sanitation improved in the 19th century, and retreated further when effective therapy was developed in the 1950s. TB was virtually forgotten until a recent resurgence in the U.S. and around the worldâ€"ominously, in forms resistant to commonly used medicines. What must the nation do to eliminate TB? The distinguished committee from the Institute of Medicine offers recommendations in the key areas of epidemiology and prevention, diagnosis and treatment, funding and organization of public initiatives, and the U.S. role worldwide. The panel also focuses on how to mobilize policy makers and the public to effective action. The book provides important background on the pathology of tuberculosis, its history and status in the U.S., and the public and private response. The committee explains how the U.S. can act with both self-interest and humanitarianism in addressing the worldwide incidence of TB.
Tuberculosis and War
Title | Tuberculosis and War PDF eBook |
Author | J.F. Murray |
Publisher | Karger Medical and Scientific Publishers |
Total Pages | 232 |
Release | 2018-03-27 |
Genre | Medical |
ISBN | 331806095X |
Tuberculosis (TB) remains the largest cause of adult deaths from any single infectious disease, and ranks among the top 10 causes of death worldwide. When TB and war occur simultaneously, the inevitable consequences are disease, human misery, suffering, and heightened mortality. TB is, therefore, one of the most frequent and deadly diseases to complicate the special circumstances of warfare. Written by internationally acclaimed experts, this book provides a comprehensive analysis of the status of TB before, during and after WWII in the 25 belligerent countries that were chiefly involved. It summarizes the history of TB up to the present day. A special chapter on “Nazi Medicine, Tuberculosis and Genocide” examines the horrendous, inhuman Nazi ideology, which during WWII used TB as a justification for murder, and targeted the disease by eradicating millions who were afflicted by it. The final chapter summarizes the lessons learned from WWII and more recent wars and recommends anti-TB measures for future conflicts. This publication is not only of interest to TB specialists and pulmonologists but also to those interested in public health, infectious diseases, war-related issues and the history of medicine. It should also appeal to nonmedical readers like journalists and politicians.